Ballentine Partners, LLC Arbutus Biopharma Corp Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q4 2024
A detailed history of Ballentine Partners, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Ballentine Partners, LLC holds 31,121 shares of ABUS stock, worth $99,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,121Holding current value
$99,587% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ABUS
# of Institutions
156Shares Held
99.6MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$69.5 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$41.2 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$28.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$26.8 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $480M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...